Immunome Notifies Availability of Press Release

Immunome, Inc.

Immunome, Inc.

IMNM

0.00
  • Immunome published a release announcing first patient dosed in a Phase 1, first-in-human trial of IM-3050 in FAP-expressing advanced solid tumors.
  • IM-3050 is a FAP-targeted radioligand therapy designed to deliver lutetium-177 to FAP-expressing cells.
  • Open-label, multicenter study will assess safety, tolerability, dosimetry, pharmacokinetics, preliminary anti-tumor activity.
  • Dose-escalation aims to set maximum tolerated dose or recommended expansion dose; expansion to further evaluate safety at that level.
  • Release posted at https://immunome.com/.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunome Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607200730BIZWIRE_USPR_____20260720_BW175949) on July 20, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.